23 Oct 2024
ZERO Biotech, a pioneering Hong Kong based nuclear medicine company, is pleased to announce the active participation at the EANM 2024 Congress held in Hamburg from October 19 to 23, 2024.
The EANM Congress, a prestigious gathering of experts in nuclear medicine, provided an invaluable platform for ZERO Biotech management to engage with industry leaders, researchers, and innovators from around the world. EANM is also an official sponsor for the 3rd annual Tackle Cancer Challenge, a global movement aiming at raising public awareness of radiotheranostic in cancer care, organised by the Oncidium Foundation. As the Hong Kong ambassador of the Oncidium Foundation, Clement Tam, CEO of ZERO Biotech took the opportunity to exchange critical updates and insights about nuclear medicine with fellow ambassadors representing diverse regions.
(Photo credit: Oncidium Foundation)
Throughout the event, ZERO Biotech management team immersed themselves in the latest advancements and breakthroughs in the field of nuclear medicine. By participating in various sessions, workshops, and discussions, they gained profound knowledge about cutting-edge developments that are shaping the future of healthcare and biotechnology.
"The EANM 2024 Congress was a remarkable experience, offering a unique opportunity to collaborate with global experts and gain deep insights into the latest trends in nuclear medicine," said Clement. "I was particularly touched by the successful case sharing by Dr. Yehia Omir, Egyptian ambassador of Oncidium Foundation and Director of PET/CT and Theranostics units, MISR Radiology Center, Egypt, that the clinical outcome of a prostate cancer patient was very promising with the radioligand therapy. It encourages me that at ZERO Biotech, we remain committed to leveraging innovative technologies and research to drive positive change in the healthcare industry."
“We have also learnt a lot from Dr. Richard Zimmermann, president of Oncidium foundation and veteran in Nuclear Medicine, about the trend in radiotheranostics through his insightful presentation as well as private conversation session,’ Clement continues.Â
ZERO Biotech continues to demonstrate its dedication to advancing healthcare through groundbreaking research, development, and collaborations. The company's participation at the EANM 2024 Congress signifies its unwavering commitment to staying at the forefront of the rapidly evolving field of nuclear medicine.